Beactica Therapeutics AB is a pharmaceutical company based in Uppsala that specializes in precision medicine aimed at treating life-threatening diseases. The company is engaged in the development of novel small molecule therapeutics and is committed to addressing significant unmet clinical needs within the healthcare sector. Beactica Therapeutics conducts advisory meetings with regulatory agencies to ensure compliance and alignment with industry standards.
The company is actively involved in research focused on the therapeutic potential of TEAD with degraders, which is part of its broader strategy to innovate in drug development. Beactica Therapeutics is scheduled to participate in the American Association for Cancer Research Annual Meeting in 2025, highlighting its ongoing contributions to cancer research. Additionally, it has been recognized as a TPD Company to Watch in 2025, reflecting its emphasis on excellence and innovation. The team at Beactica is noted for its exceptional scientific expertise and passion for advancing therapeutic options, and the company also offers investment opportunities in its research initiatives.